Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant
| Autor: | Simu K. Thomas, Julie Heroux, Geneviève Gauthier, Lei Chen, Richard T. Maziarz, Annie Guerin, Maryia Zhdanava, Eric Q. Wu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
business.industry Lymphoblastic Leukemia Hematology 03 medical and health sciences Indirect costs 0302 clinical medicine Outpatient visits Oncology Laboratory service 030220 oncology & carcinogenesis Health care medicine Pharmacology (medical) Stem cell Intensive care medicine business health care economics and organizations Resource utilization Research Article 030215 immunology |
| Zdroj: | International Journal of Hematologic Oncology. 5:63-75 |
| ISSN: | 2045-1407 2045-1393 |
| DOI: | 10.2217/ijh-2016-0001 |
| Popis: | Aim: To assess the 5-year healthcare resource utilization (HRU) and direct payer costs following allogeneic hematopoietic stem cell transplants (HSCTs) in acute lymphoblastic leukemia pediatric patients using data from two large US administrative databases. Patients & methods: Among the 209 patients with acute lymphoblastic leukemia, HRU and costs were described over the up to 5 years after the HSCT. Results: HRU and costs following the HSCTs were substantial. The highest average costs and most intensive HRU were observed within the first year following the HSCTs (49 outpatient visits; 29 laboratory service visits; 68 inpatient days), with a first year cost of US$683,099 and substantial costs over the following years. Conclusion: HRU and direct costs associated with allogeneic HSCTs are substantial. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|